In Chedraui et al.’s study [43], an increase in IL-6 and a decrease in urokinase-type plasminogen activator levels in postmenopausal women have been introduced as the reasons for the effects of these hormonal changes on the occurrence of the MetS. This evidence concerns the gene PLAU and metabolic syndrome.